Profit from the Genomics Market Momentum With These ETFs Sweta Jaiswal, Frm - Zacks Investment Research - Fri May 22, 2:43PM CDT Sweta Jaiswal, Frm - ZACKS - Fri May 22, 2:43PM CDT
Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.
Biotech ETFs to Gain From Latest Advancements in Cancer Drugs Sweta Jaiswal, Frm - Zacks Investment Research - Wed May 13, 4:26PM CDT Sweta Jaiswal, Frm - ZACKS - Wed May 13, 4:26PM CDT
The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.
Biotech ETFs Gain on New Positive Data for Gilead's Remdesivir Sweta Jaiswal, Frm - Zacks Investment Research - Thu Apr 30, 3:50PM CDT Sweta Jaiswal, Frm - ZACKS - Thu Apr 30, 3:50PM CDT
As the coronavirus continues to spread, the latest positive data on remdesivir is some relief in such challenging times.
First-Mover Pandemic Disease Fight ETF On The Way Sweta Killa - Zacks Investment Research - Tue Apr 28, 9:35AM CDT Sweta Killa - ZACKS - Tue Apr 28, 9:35AM CDT
Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.
Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners Sanghamitra Saha - Zacks Investment Research - Fri Apr 24, 1:30PM CDT Sanghamitra Saha - ZACKS - Fri Apr 24, 1:30PM CDT
Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 5:23AM CST Zacks Equity Research - ZACKS - Thu Feb 27, 5:23AM CST
Sector ETF report for PBE
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks Equity Research - Zacks Investment Research - Wed Feb 5, 5:34AM CST Zacks Equity Research - ZACKS - Wed Feb 5, 5:34AM CST
Sector ETF report for PBE
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 6:58AM CST Zacks Equity Research - ZACKS - Mon Jan 13, 6:58AM CST
Sector ETF report for PBE
Will Biotech ETFs Excel in Election Year Post a Surge in 2019? Sanghamitra Saha - Zacks Investment Research - Mon Dec 23, 11:00AM CST Sanghamitra Saha - ZACKS - Mon Dec 23, 11:00AM CST
Can biotech ETFs repeat its success story of 2019 in the election year of 2020?
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks Equity Research - Zacks Investment Research - Thu Dec 19, 6:05AM CST Zacks Equity Research - ZACKS - Thu Dec 19, 6:05AM CST
Sector ETF report for PBE
A Guide to Biotech ETF Investing Sweta Jaiswal, Frm - Zacks Investment Research - Mon Dec 2, 1:40PM CST Sweta Jaiswal, Frm - ZACKS - Mon Dec 2, 1:40PM CST
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks Equity Research - Zacks Investment Research - Wed Nov 27, 5:52AM CST Zacks Equity Research - ZACKS - Wed Nov 27, 5:52AM CST
Sector ETF report for PBE
Genomics ETFs Surge on CRISPR's Gene Editing Progress Sweta Jaiswal, Frm - Zacks Investment Research - Mon Nov 25, 5:55PM CST Sweta Jaiswal, Frm - ZACKS - Mon Nov 25, 5:55PM CST
The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks Sanghamitra Saha - Zacks Investment Research - Thu Nov 14, 12:00PM CST Sanghamitra Saha - ZACKS - Thu Nov 14, 12:00PM CST
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Sweta Killa - Zacks Investment Research - Tue Nov 5, 7:32AM CST Sweta Killa - ZACKS - Tue Nov 5, 7:32AM CST
Sector ETF report for PBE
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Sweta Killa - Zacks Investment Research - Fri Sep 20, 10:04AM CDT Sweta Killa - ZACKS - Fri Sep 20, 10:04AM CDT
Sector ETF report for PBE
ETFs Poised to Benefit from Gene Editing Revolution Sweta Jaiswal, Frm - Zacks Investment Research - Fri Sep 6, 2:07PM CDT Sweta Jaiswal, Frm - ZACKS - Fri Sep 6, 2:07PM CDT
Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.
ETFs to Gain From the Booming Genomics Market Sweta Jaiswal, Frm - Zacks Investment Research - Wed Sep 4, 2:18PM CDT Sweta Jaiswal, Frm - ZACKS - Wed Sep 4, 2:18PM CDT
Rising investments, surging demand for personalized medicines and shrinking sequencing costs are a slew of factors favouring the genomics space. We look at a few ETFs that can cash in on this trend.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks Equity Research - Zacks Investment Research - Thu Aug 29, 6:39AM CDT Zacks Equity Research - ZACKS - Thu Aug 29, 6:39AM CDT
Sector ETF report for PBE
Amgen to Buy Celgene's Otezla: 5 ETF Drugs Sweta Killa - Zacks Investment Research - Tue Aug 27, 9:05AM CDT Sweta Killa - ZACKS - Tue Aug 27, 9:05AM CDT
Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.
